gsk pipeline | Pipeline

Keyword	CPC	PCC	Volume	Score	Length of keyword
gsk pipeline	1.46	0.1	4861	26	12
gsk	0.44	0.4	9037	87	3
pipeline	0.59	1	5679	80	8

Keyword	CPC	PCC	Volume	Score
gsk pipeline	0.95	0.3	3695	41
gsk pipeline 2024	1.7	0.8	1898	68
gsk pipeline 2023	1.24	0.1	9778	65
gsk pipeline 2022	0.46	0.3	7626	21
gsk pipeline oncology	0.65	1	7747	50
gsk pipeline vaccines	0.69	0.3	6554	56
gsk pipeline pdf	1.77	0.6	7776	28
gsk pipeline chart	1.59	0.2	1183	41
gsk pipeline products	1.24	1	6275	30
gsk pipeline uk	0.55	0.1	1297	66
gsk pipeline 2021	1.73	0.5	4042	99
gsk pipeline update	0.58	0.3	1206	91
gsk pipeline hepatology	1.3	0.3	9997	25
gsk pipeline presentation	0.21	0.9	9924	14
gsk vaccine pipeline	1.25	0.5	5767	42
gsk r&d pipeline	1.03	0.7	6958	69
gsk drug pipeline	1.02	0.9	1157	4
us pipeline forecasting manager gsk	1.17	0.5	6762	53
director pipeline project management gsk	1.93	0.5	9600	23

Search Results related to gsk pipeline on Search Engine

Pipeline | GSK
gsk.com

https://www.gsk.com/en-gb/innovation/pipeline/

WebAt GSK, our portfolio and pipeline is focused in developing vaccines and medicines in four core therapeutic areas, which are the areas of human health we focus on to prevent and treat disease: infectious diseases, HIV, respiratory/immunology and oncology.

DA: 22 PA: 61 MOZ Rank: 49

Pipeline assets and clinical trials appendix - GSK
gsk.com

https://www.gsk.com/media/10927/fy-2023-pipeline-assets-and-clinical-trials-report.pdf

WebDescription. A randomized, active-controlled, observer-blind study to assess the safety, reactogenicity, and immunogenicity of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults who previously received a complete primary vaccination series with or without booster dose(s) Timeline.

DA: 34 PA: 74 MOZ Rank: 100

Research and development approach | GSK
gsk.com

https://www.gsk.com/en-gb/innovation/research-and-development-approach/

WebR&D is the core of our innovation. In 2023, our R&D expenditure was £6.2 billion, up 13.4% AER and 13.6% CER on 2022. We’ve also strengthened our pipeline and technology capabilities through business development, seeking out new, differentiated opportunities in diseases with high patient need.

DA: 84 PA: 83 MOZ Rank: 70

GSK Oncology Pipeline
gsk.com

https://medical.gsk.com/content/cf-pharma/medicalaffairs/master/home/oncology-portal/pipeline.html

WebOur unique R&D approach of Science x Technology x Culture is helping to fight cancer on multiple groundbreaking fronts – focusing on maximizing survival through the discovery and development of novel oncology medicines that may have life-changing potential.

DA: 89 PA: 10 MOZ Rank: 90

Therapeutic areas | GSK
gsk.com

https://www.gsk.com/en-gb/innovation/therapeutic-areas/

WebWe are bringing stronger alignment to our core therapeutic areas and embedding tech to accelerate research to deliver our pipeline better and faster. Our portfolio and pipeline is focused in four core therapeutic areas, which are the areas of human health we focus on to prevent and treat disease.

DA: 80 PA: 53 MOZ Rank: 4

Pipeline | Vaccines | GSK US Medical Affairs
gskusmedicalaffairs.com

https://gskusmedicalaffairs.com/vaccines/pipeline/

WebAt GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines. Our products in development progress through three stages: phase I, phase II, and phase III/registrational.

DA: 85 PA: 58 MOZ Rank: 43

GSK unveils latest research advances demonstrating strength of …
gsk.com

https://us.gsk.com/en-us/media/press-releases/gsk-unveils-latest-research-advances-demonstrating-strength-of-its-portfolio-and-pipeline-at-asco-and-eha/

WebGSK is focused on maximizing patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality.

DA: 11 PA: 10 MOZ Rank: 42

About JEMPERLI (dostarlimab-gxly) - GSK
gsk.com

https://us.gsk.com/en-us/media/press-releases/gsk-receives-fda-accelerated-approval-for-jemperli-dostarlimab-gxly-for-adult-patients-with-mismatch-repair-deficient-dmmr-recurrent-or-advanced-solid-tumors/

WebAug 17, 2021 · GSK’s pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone ...

DA: 28 PA: 75 MOZ Rank: 41

GSK to highlight continued progress in oncology pipeline and …
gsk.com

https://us.gsk.com/en-us/media/press-releases/gsk-to-highlight-continued-progress-in-oncology-pipeline-and-portfolio-with-data-presented-at-esmo/

WebGSK has a diverse portfolio and pipeline, including three marketed oncology medicines and 16 assets in clinical development that leverage the science of the immune system, human genetics and advanced technologies to address a variety of tumour types. Continuing to advance immuno-oncology therapies.

DA: 6 PA: 94 MOZ Rank: 8

Innovation | GSK US
gsk.com

https://us.gsk.com/en-us/innovation/

WebAs a global biopharma company, we invest heavily in our industry-leading pipeline of new products and specialty medicines that help us to get ahead of disease together. View our Pipeline progress on our global site

DA: 15 PA: 39 MOZ Rank: 24